Study details
Enrolling now
A Phase 1 Trial of Orca-Q
Orca Biosystems, Inc.
NCT IDNCT03802695ClinicalTrials.gov data as of Apr 2026
Phase
Phase 1
Target enrollment
300
Study length
about 8.7 years
Ages
12–78
Locations
9 sites in CA, FL, GA +4
About this study
This trial is testing the safety and how well Orca-Q works in people who are getting a bone marrow transplant for leukemia, mixed phenotype acute leukemia, or myelodysplastic syndromes. The treatment type is biological medication.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive OrcaGraft (Orca-Q)
PhasePhase 1
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low15%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Endpoints
Secondary: Disease-free Survival (DFS) through Day +365, GVHD-free and Relapse-free Survival (GRFS) through Day +365, Overall Survival through Day +365
Body systems
Oncology